COVID-19 vaccine race: watch your step for cancer patients
Raphaëlle Fanciullino, Joseph Ciccolini, G. Milano
Abstract
Patients with cancer should benefit from COVID-19 vaccination. Some of the most advanced vaccine candidates are mRNAs encapsulated into lipid carriers, and small liposomes are expected to accumulate in tumour tissues through the enhanced and permeation retention effect. However, to what extent solid tumours could take up a significant part of the vaccine dose as well remains unknown. This calls for a careful evaluation of the efficacy of these promising mRNA COVID-19 vaccines administered as lipid carriers for patients with solid tumours, including a possible re-appraisal of the dosing for optimal protection of this specific and frail population.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Race (biology)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyMedicineCancerInternal medicineGender studiesSociologyInfectious disease (medical specialty)OutbreakDiseaseCOVID-19 and healthcare impactsSARS-CoV-2 and COVID-19 ResearchCancer Immunotherapy and Biomarkers